Introduction
The treatment of ventricular septal defect (VSD) depends on the size of the hole in the interventricular septum, the amount of shunting between the ventricles, the symptoms it causes, and whether the defect is likely to close on its own. Treatments include observation, medications that reduce the physiological consequences of the defect, catheter-based closure, and surgical repair. These approaches do not all act in the same way: some reduce the workload imposed on the heart and lungs, while others physically eliminate the abnormal opening that allows blood to pass between the left and right ventricles.
A VSD creates an abnormal communication between the two pumping chambers of the heart. Because pressure in the left ventricle is normally higher than in the right ventricle, oxygen-rich blood tends to move through the defect into the right ventricle. This left-to-right shunt increases blood flow to the lungs and can enlarge the left side of the heart over time. Treatment is designed to reduce symptoms, prevent heart failure and pulmonary vascular injury, support normal growth and function in children, and, when necessary, close the defect so circulation can return to a more normal pattern.
Understanding the Treatment Goals
The central goal in VSD treatment is to match the intervention to the hemodynamic burden created by the defect. A small defect may produce little or no significant shunting, so the goal is often monitoring rather than active repair. A larger defect can cause substantial volume overload of the pulmonary circulation and left heart, leading to tachypnea, poor feeding in infants, exercise intolerance, or signs of congestive heart failure. In these cases, treatment aims to reduce the consequences of the shunt and protect the myocardium and lungs from chronic stress.
Another goal is prevention of long-term complications. Persistent large shunts can lead to pulmonary hypertension because the lung vessels are exposed to excessive flow and pressure. Over time, vascular remodeling may become irreversible. Early treatment in appropriate cases is therefore intended to interrupt this process before the pulmonary circulation adapts in a harmful way. Closure also reduces the risk of recurrent infections in the heart and may improve growth and functional capacity when the defect has been causing significant physiologic strain.
Treatment decisions are guided by whether the defect is restrictive or nonrestrictive, whether there is evidence of left heart dilation, whether pulmonary pressures are rising, and whether the defect is producing symptoms or failure to thrive. The biologic target is not simply the hole itself, but the abnormal pressure and flow relationships it creates.
Common Medical Treatments
Medical treatment does not close the defect, but it helps manage the physiology created by the shunt. The most common medications are diuretics, afterload-reducing agents, and, in some cases, agents that support cardiac function. Diuretics such as furosemide decrease intravascular volume by increasing renal excretion of sodium and water. In a child with a significant VSD, reducing circulating volume lowers pulmonary congestion and decreases the filling pressures that contribute to heart failure symptoms. This does not stop blood from crossing the defect, but it reduces the amount of fluid backing up into the lungs and eases the work of the ventricles.
In selected cases, medications that reduce afterload may be used. By lowering systemic vascular resistance, these agents can reduce the pressure against which the left ventricle must pump. In some patients this can lessen ventricular workload and improve forward output, although the effect on shunt magnitude varies and depends on the relative pressures in the systemic and pulmonary circuits. The mechanism is hemodynamic rather than structural: the drug alters pressure gradients that influence blood flow through the defect.
If heart failure symptoms are present, additional medication may be used to support myocardial performance and control congestion. These treatments are aimed at the secondary effects of the defect, not the defect itself. They are especially useful in infants with large shunts while waiting for spontaneous reduction, growth, or definitive closure. In patients with mild defects and no physiologic burden, medications may not be necessary at all.
Procedures or Interventions
When a VSD is large, symptomatic, or causing complications, the most direct treatment is closure of the defect. Closure can be achieved surgically or, in some anatomically suitable cases, by transcatheter device placement. The purpose of both approaches is to eliminate the abnormal communication between the ventricles so that left ventricular pressure no longer drives blood into the right ventricle.
Surgical repair is often used for defects that are too large, too close to important valves, or too anatomically complex for catheter-based closure. The surgeon opens the heart, identifies the defect, and closes it with sutures or a patch. The patch acts as a physical barrier that restores the integrity of the interventricular septum. Once the opening is closed, the left-to-right shunt is eliminated or markedly reduced, pulmonary overcirculation declines, and the left ventricle is relieved of the extra volume load.
Transcatheter closure uses a device delivered through blood vessels, usually from the femoral vein. Under imaging guidance, the device is positioned across the defect and expands to seal the opening. This approach is most appropriate for selected muscular VSDs and some other anatomically favorable defects. The mechanism is the same as surgery: the device creates a barrier that blocks shunt flow. The advantage is that it avoids open-heart surgery, but its feasibility depends strongly on defect size, location, and surrounding structures.
In infants with severe symptoms who are not ready for definitive closure or when the anatomy is unfavorable, a temporary surgical procedure may be used in rare cases. Pulmonary artery banding reduces blood flow to the lungs by narrowing the pulmonary artery. This decreases pulmonary overcirculation and protects the lung vasculature while the child grows or until complete repair can be performed. It does not close the VSD, but it reduces the downstream hemodynamic impact of the shunt.
Supportive or Long-Term Management Approaches
Supportive management is centered on observing the natural history of the defect and monitoring for physiologic change. Many small VSDs close spontaneously during infancy or early childhood as surrounding tissue grows and the defect becomes smaller relative to the septum. Follow-up with echocardiography allows clinicians to measure shunt size, chamber dimensions, estimated pulmonary pressure, and valvular function. This monitoring helps determine whether the defect remains hemodynamically insignificant or whether it is becoming more consequential over time.
Nutritional and growth support is often part of long-term management in infants with larger shunts. Increased metabolic demand and feeding fatigue can occur because the heart is working harder and the respiratory rate may be elevated. Supportive care aims to maintain adequate energy intake while the underlying physiology is monitored or treated. The biological rationale is straightforward: if cardiac output is being diverted inefficiently through the shunt, the body may require more calories and careful fluid balance to sustain normal growth.
Long-term management also includes surveillance for complications such as aortic valve prolapse, aortic regurgitation, arrhythmias, and pulmonary hypertension. Some VSDs, especially those near the outlet portion of the septum, can alter the support of the aortic valve leaflet. Imaging follow-up identifies these changes before they produce major dysfunction. In patients whose defects are closed, continued follow-up is needed to confirm that ventricular function remains stable and that no residual shunt or valve problem has developed.
Factors That Influence Treatment Choices
Defect size is one of the most important factors. A small restrictive VSD allows only a limited shunt because the pressure gradient across the defect is reduced by the small opening. These defects may cause a loud murmur but little hemodynamic compromise, so observation is often sufficient. A large nonrestrictive VSD permits substantial blood flow between the ventricles and may produce early heart failure, poor weight gain, or elevated pulmonary pressures. These cases are more likely to require closure.
Age influences treatment because many VSDs in infants are managed initially with observation and medication while waiting to see whether spontaneous closure occurs. In older children or adults, persistent defects are less likely to resolve and are more often evaluated for definitive repair. The general health of the individual also matters, since associated congenital abnormalities, prematurity, lung disease, or genetic syndromes can change operative risk and the timing of intervention.
The location of the defect affects treatment selection. Muscular defects may be suitable for transcatheter closure if anatomy permits, while perimembranous or outlet defects may require surgery because of their proximity to the conduction system or valves. Prior response to medication is also relevant. If diuretics and other supportive therapies control symptoms and the defect is trending toward spontaneous closure, conservative management may continue. If there is persistent heart failure, chamber enlargement, or rising pulmonary pressure despite medical therapy, closure becomes more urgent.
Potential Risks or Limitations of Treatment
Medical therapy has limitations because it cannot remove the anatomical defect. Diuretics and related medications can improve congestion but may not fully prevent the consequences of a large shunt. In infants, excessive diuresis can also affect electrolyte balance and fluid status. These risks arise from the way the drugs alter renal handling of salt and water, which is helpful for congestion but can be physiologically disruptive if overused.
Surgical repair is highly effective, but it carries risks associated with open-heart surgery and cardiopulmonary bypass. These include bleeding, infection, arrhythmia, residual shunt, and, in some cases, injury to the conduction system leading to heart block. The conduction tissue runs close to parts of the septum, so closure in the wrong plane can interfere with electrical signaling between atria and ventricles. There is also a possibility of valve dysfunction if the defect is near the aortic or tricuspid valve.
Transcatheter closure avoids open surgery but has its own limitations. Not all defects are anatomically suitable, and device placement can interfere with nearby valves or the conduction system. A device may embolize or leave a residual shunt if seating is incomplete. In rare cases, erosion or late rhythm disturbances may occur. Pulmonary artery banding, while useful as a temporary measure, adds its own surgical burden and is not a definitive solution; it manages the hemodynamic effect rather than correcting the septal opening.
Conclusion
Ventricular septal defect is treated according to the physiologic burden it creates. Small, asymptomatic defects are often monitored because many close spontaneously and do not significantly disturb circulation. Larger or symptomatic defects may require medication to reduce heart failure symptoms and decrease the workload on the heart, while definitive treatment relies on closing the abnormal opening by surgery or catheter-based device placement. In selected severe cases, temporary procedures can reduce pulmonary overcirculation until definitive repair is possible.
Across all approaches, the underlying principle is the same: treatment addresses the abnormal pressure and flow relationships caused by the defect. Medications modify the consequences of the shunt, while procedural interventions eliminate the shunt itself. By reducing left-to-right flow, protecting the lungs from excessive pressure and volume, and restoring more normal cardiac mechanics, treatment aims to preserve heart function and prevent long-term complications.